Roche
Indianapolis
Indiana
United States
2130 articles about Roche
-
Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab
5/17/2023
Roche announced that it will be showcasing innovative laboratory solutions and digital diagnostics through - "Innovation Past, Present and Future" at this year's WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May.
-
Fenebrutinib in a mid-phase trial reduced brain legions in relapsing forms of multiple sclerosis, the company reported. It is the only reversible BTK inhibitor currently in Phase III MS trials. -
The layoffs will go into effect on July 25, according to a Worker Adjustment and Retraining Act (WARN) notice filed in April.
-
During a first-quarter earnings call, Novo revealed its hemophilia candidate had been blocked by the FDA, and that the company is reducing the U.S. supply of lower doses of weight-loss drug Wegovy. -
Hasten Biopharma Acquires Commercial Rights in China for Roche's Antibiotic Rocephin®
5/4/2023
Hasten Biopharmaceutic Co., Ltd announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.
-
Polivy is approved for front-line DLBCL as part of a combination regimen including Rituxan, cyclophosphamide, doxorubicin and prednisone. -
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma. -
Top Biotech Licensing Deals of Q1 2023
3/30/2023
There have already been several big biotech licensing deals in Q1. See inside for some of this quarter's biggest licensing deals — from the surprising and pivotal to the lucrative and consequential. -
The FDA is expected to make decisions on Emergent BioSolutions' sNDA for OTC Narcan and Roche's Polivy in frontline DLBCL. -
An independent panel of advisers voted to approve Genentech's Polivy after internal FDA staff raised concerns regarding the efficacy and risk-benefit profile as a first-line treatment for large B-cell lymphoma. -
FDA Action Alert: Roche and Acadia
3/6/2023
The FDA's Oncologic Drugs Advisory Committee will meet March 9 to discuss Roche's sBLA for Polivy in first-line DLBCL, while Acadia awaits potential approval of the first therapy for Rett Syndrome. -
Phase III data showed the combination of Roche’s Tecentriq and Exelixis’ Cabometyx fell short of its primary endpoint in renal cell carcinoma. -
Roche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemics
2/28/2023
Roche announced the expansion of its collaboration with the U.S. Centers for Disease Control and Prevention to strengthen laboratory capabilities in countries greatly affected by the HIV and tuberculosis epidemics.
-
Amid mounting pressure from investors and shareholders, Bayer’s supervisory board unanimously appointed outsider Bill Anderson as its new CEO. -
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
2/9/2023
Roche announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.
-
Data from a Phase III study show Genentech’s crovalimab is non-inferior to AstraZeneca’s Soliris, the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH). -
Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, as well as several other candidates.
-
Roche's Tecentriq (atezolizumab) combined with Avastin (bevacizumab) met the primary efficacy endpoint in early-stage hepatocellular carcinoma in the Phase III IMbrave050 study.
-
HKSTP and Roche join hands in strategic collaboration
1/18/2023
Hong Kong Science and Technology Parks (HKSTP) announced a strategic collaboration with Roche, one of the world’s largest pharmaceutical companies, with the aim of leading HK and the Greater Bay Area in becoming a pioneer in life science innovation and to be an example for the region.
-
Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
1/9/2023
Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, announced a clinical collaboration agreement with Roche.